Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204127 | 0.89 | PTGS2 (0.70) | PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL6958517 | 0.88 | PTGS2 (0.67) | PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL5273708 | 0.88 | PTGS2 (0.67) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL5205129 | 0.87 | PTGS2 (0.62) | PTGS2PTGS1PDPK1 | |
| SCHEMBL5204716 | 0.85 | PTGS2 (0.62) | PTGS2PTGS1KEAP1CYP2C9PDPK1 | |
| SCHEMBL5205170 | 0.84 | KDM4E (0.48) | PTGS2PTGS1KEAP1CYP2C9EPHX2 | |
| SCHEMBL5205952 | 0.84 | CA2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL4674149 | 0.84 | PDPK1 (0.69) | PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL5204541 | 0.82 | PTGS2 (0.55) | PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL5202832 | 0.82 | PTGS2 (0.65) | PTGS2PTGS1CYP2C9PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539718-A4 | 1,2,4-TRIAZOLE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ CORP (KR) | 2007-08-01 | — | — | EP | disclosed |
| US-7019144-B2 | 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | CJ CORP. (KR) | 2006-03-28 | — | — | US | disclosed |
| EP-1539718-A1 | 1,2,4-TRIAZOLE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ Corporation (KR) | 2005-06-15 | — | — | EP | disclosed |
| US-20050075507-A1 | 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | CJ CHEILJEDANG CORPORATION (KR) | 2005-04-07 | — | — | US | disclosed |
| WO-2004014878-A1 | 1,2,4-TRIAZOLE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ CORPORATION (KR) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075507-A1 | 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | CYP4B1, CYP3A5, CYP7A1 | PTGS2 1769/4885PTGS1 523/4885KEAP1 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.